167 related articles for article (PubMed ID: 32590405)
1. Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder.
Gomeni R; Komolova M; Incledon B; Faraone SV
J Clin Psychopharmacol; 2020; 40(4):350-358. PubMed ID: 32590405
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
Childress AC; Cutler AJ; Marraffino A; McDonnell MA; Turnbow JM; Brams M; DeSousa NJ; Incledon B; Sallee FR; Wigal SB
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511
[No Abstract] [Full Text] [Related]
3. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.
Teuscher NS; Sikes CR; McMahen R; Engelking D
J Clin Psychopharmacol; 2018 Oct; 38(5):467-474. PubMed ID: 30119076
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.
Liu T; Gobburu JVS; Po MD; McLean A; DeSousa NJ; Sallee FR; Incledon B
J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):181-191. PubMed ID: 30810347
[TBL] [Abstract][Full Text] [Related]
7. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
Wigal SB; Gupta S; Heverin E; Starr HL
J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
[TBL] [Abstract][Full Text] [Related]
9. A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial.
Childress AC; Uchida CL; Po MD; DeSousa NJ; Incledon B
Clin Ther; 2020 Dec; 42(12):2332-2340. PubMed ID: 33168234
[TBL] [Abstract][Full Text] [Related]
10. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
Silva RR; Brams M; McCague K; Pestreich L; Muniz R
Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
[TBL] [Abstract][Full Text] [Related]
11. Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder.
López FA; Faraone SV; Newcorn JH; Doll HA; Rhoten S; Lewis HB; Khan TF; DeSousa NJ; Sallee FR; Incledon B
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):179-186. PubMed ID: 33797983
[No Abstract] [Full Text] [Related]
12. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
[TBL] [Abstract][Full Text] [Related]
14. The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
Childress A; Belchenko D; Lempa B
Expert Rev Neurother; 2017 Feb; 17(2):113-121. PubMed ID: 27936986
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
17. Effect of Colonic Absorption on the Pharmacokinetic Properties of Delayed-Release and Extended-Release Methylphenidate: In Vivo, In Vitro, and Modeling Evaluations.
Incledon B; Incledon C; Gomeni R; Uchida CL; Morris A; Perry K; Kapuscinski J
Clin Pharmacol Drug Dev; 2022 Aug; 11(8):966-975. PubMed ID: 35316579
[TBL] [Abstract][Full Text] [Related]
18. Adverse Events During Dosing of Delayed-release/Extended-release Methylphenidate: Learnings From the Open-label Phase of a Registration Trial and a Real-world Postmarketing Surveillance Program.
Katzman MA; Otcheretko V; Po MD; Uchida CL; Incledon B
Clin Ther; 2023 Dec; 45(12):1212-1221. PubMed ID: 37770309
[TBL] [Abstract][Full Text] [Related]
19. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
[TBL] [Abstract][Full Text] [Related]
20. Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Pearson DA; Santos CW; Aman MG; Arnold LE; Lane DM; Loveland KA; Mansour R; Ward AR; Casat CD; Jerger S; Schachar RJ; Bukstein OG; Cleveland LA
J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):414-426. PubMed ID: 32644833
[No Abstract] [Full Text] [Related]
[Next] [New Search]
